Methotrexate is a potent, competitive inhibitor of dihydrofolate reductase (DHFR), and reduces metabolically active intracellular folates decreasing the de novo synthesis of purines and pyrimidines (precursors of DNA and RNA) required for cellular proliferation. Disease-modifying anti-rheumatic drug (DMARD).

KEYWORDS: Methotrexate | supplier | DHFR reductase inhibitor | Amethopterin | MTX | 4-Amino-10-methylfolic acid | CAS [59-05-2] | [15475-56-6] | [7413-34-5] | Dihydrofolic acid | DHFR | Inhibitor | Enzymes | Rheumatoid arthritis | Psoriasis | Multiple sclerosis